CRL - Charles River brokers gene therapy manufacturing pact with Navega Therapeutics
2024-03-14 10:27:07 ET
More on Charles River Laboratories
- Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
- Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript
- DURECT and Charles River enter agreement for alzet in U.S., Canada
- Charles River Labs stock hits 52-week high
- Seeking Alpha’s Quant Rating on Charles River Laboratories